Trial Profile

A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nemtabrutinib (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine; Rituximab
Indications Chronic lymphocytic leukaemia; Lymphoid leukaemia
Focus Registrational; Therapeutic Use
Acronyms BELLWAVE-008
Sponsors Merck Sharp & Dohme

24 Dec 2024 Status changed from recruiting to active, no longer recruiting.
28 Sep 2023 Planned End Date changed from 7 Feb 2031 to 17 Mar 2031.
28 Sep 2023 Planned primary completion date changed from 7 May 2027 to 19 May 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com